Smart ring maker Oura announced on Tuesday that it is acquiring Counsel Health for $625 million. The deal comes a few weeks after Oura postponed its up to $2.2 billion IPO indefinitely, citing market uncertainty that disrupted public listing timelines. Instead of facing public market scrutiny amid hardware commoditization and rising pressure from rivals like RingConn and Ultrahuman, Oura chose to deploy its capital directly into vertical integration, securing an AI healthcare layer to transform its business model from a pure hardware vendor into a recurring-revenue clinical ecosystem.
Counsel Health is an AI-powered healthcare platform that combines a chat-based medical experience with access to licensed physicians.
Shifting Capital from the Public Market to Clinical AI
While Oura has dominated the smart ring market for years, rivals like RingConn and Ultrahuman are emerging to challenge its position, putting pressure on the company to accelerate its product diversification. Shelving the IPO in favor of a major acquisition reveals a strategic calculation: public markets demand immediate, predictable margins that can clash with the heavy R&D investments required to scale an AI-native healthcare service. By keeping private, Oura avoids the short-term earnings pressure of public listings, redirecting financial resources toward securing proprietary clinical infrastructure that hardware-only competitors cannot easily replicate.
"Oura helps members understand their physiology and, with Counsel, they can take action on their health across a range of needs, from quick questions and prescriptions to lab results, chronic care, and referrals," as Oura CEO Tom Hale stated in the press release.
Counsel Health raised a $25 million Series A a year ago, led by Andreessen Horowitz (a16z) and GV. PitchBook estimates that the startup had raised a total of $36 million prior to the acquisition, making this $625 million exit a substantial return for early investors while giving Oura immediate access to mature clinical AI technology.
How does this combination function inside the core product?
Its service was integrated into the Oura app in June. Now, the companies plan to expand on their existing partnership to build across preventative care, acute care, and specialty and chronic care. For a hardware-first smart ring company, executing a subscription-based AI healthcare pivot carries a distinct brand dilution risk; users accustomed to buying a physical biometric tracker may resist being upsold into clinical care tiers. However, by embedding physician-backed interventions directly into the app, Oura attempts to bridge the gap between passive health monitoring and active medical treatment.
Unit Economics and Platform Execution
The unit economics of combining high-margin hardware sales with software-driven healthcare services depend heavily on lifetime value expansion. As Bloomberg reported, Counsel CEO Muthu Alagappan will join Oura as chief clinical AI officer, alongside the company's 70 employees. Following the acquisition, Oura explained that Counsel will continue serving existing and new enterprise partners, with the goal of expanding its AI-native care model to a broader user base beyond Oura's existing membership, thereby diversifying revenue streams away from pure device upgrades.
"At Counsel, we've built medical AI around trust, safety and responsibility, keeping physicians in the loop for clinical decisions," as Alagappan commented.
For the quarter ended on September 30, Oura announced that its revenue grew 153% year-over-year to $533 million. For its fiscal year 2026, Oura generated revenue of approximately $1.75 billion, marking 92% year-over-year growth. The company reached an $11 billion valuation following a $900 million late-stage funding round in October 2025, providing the robust balance sheet necessary to absorb a $625 million cash-and-stock-level transaction without immediate reliance on public equity markets.
The deal is expected to close before the end of 2027.
Why it matters
Hardware margins face an immediate risk of commoditization unless backed by software lock-in, which explains Oura’s $625 million bet on Counsel Health. Sidestepping public scrutiny after shelving its planned listing, the company redirected its balance sheet into proprietary infrastructure that pure device makers cannot replicate. The acquired licensed network and conversational layer directly shield its core business from cheaper rivals like RingConn and Ultrahuman. Whether an engineering team and 70 healthcare specialists can convert simple biometric tracking into a recurring clinical service remains the real operational test.